MCC Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The MCC gene, located at 5q21.2, encodes a multifunctional scaffold protein that acts as a tumor suppressor by negatively regulating Wnt/β-catenin signaling, modulating the mitotic spindle checkpoint, and promoting apoptosis.
• MCC protein exhibits a modular domain architecture, including an N-terminal Armadillo repeat region for β-catenin binding, a coiled-coil domain for APC interaction, and a C-terminal domain for further β-catenin sequestration and BAX interaction.
• Pathogenic alterations in MCC are predominantly truncating somatic mutations (frameshift, nonsense) in epithelial malignancies like colorectal, hepatocellular, and gastric cancers, with a recurrent frameshift mutation (c.286delA) in MSI-high colorectal tumors.
• Epigenetic silencing via promoter CpG island hypermethylation is a significant mechanism of MCC inactivation in 20-30% of sporadic colorectal cancers, correlating with loss of mRNA expression.
• MCC plays a role in viral oncogenesis, with HPV E6 and HBV HBx proteins promoting MCC degradation, thereby contributing to Wnt pathway activation and genomic instability in cervical and hepatocellular carcinomas, respectively.
• Therapeutic strategies for MCC dysfunction focus on restoring its tumor suppressor activity through demethylating agents, inhibiting its degradation, or gene therapy, with potential for synthetic lethality approaches targeting MPS1 in MCC-deficient tumors.

Executive Summary & Key Metadata

The mutated in colorectal cancers (MCC) gene encodes a multifunctional scaffold protein that operates at the intersection of Wnt/β-catenin signaling, cell cycle control, and apoptosis. Originally identified through positional cloning efforts targeting chromosome 5q21 in familial adenomatous polyposis (FAP) patients, MCC was initially overshadowed by its neighboring tumor suppressor, APC. However, subsequent functional genomics have established MCC as an independent regulator of mitotic progression, a negative modulator of β-catenin/TCF transcriptional activity, and a haploinsufficient tumor suppressor in multiple epithelial malignancies. This reference manual provides a comprehensive, biophysically grounded analysis of the MCC gene locus, its protein product's three-dimensional architecture, its integration into cellular signaling networks, the clinical spectrum of pathogenic variants, and emerging therapeutic strategies.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Context and Physical Mapping

The MCC gene resides on the long arm of chromosome 5 at cytogenetic band 5q21.2, a genomic region of approximately 55 kilobases (kb) spanning from 112,541,000 to 112,596,000 base pairs on the forward strand of GRCh38. This locus is notable for its proximity to the adenomatous polyposis coli (APC) gene, located approximately 400 kb centromeric to MCC. The two genes share a common evolutionary ancestry, with both encoding proteins containing Armadillo/β-catenin-like repeats, yet they have diverged functionally. The 5q21 region is a well-established "mutational hotspot" in sporadic colorectal cancer, where loss of heterozygosity (LOH) events frequently delete both APC and MCC simultaneously, complicating the attribution of tumor suppressor activity to either gene individually.

The MCC gene is oriented in a head-to-tail configuration relative to APC, with its promoter region positioned toward the telomere. The intergenic region between MCC and the downstream gene DPH5 (diphthamide biosynthesis 5) contains multiple conserved non-coding elements (CNEs) that function as enhancers for both MCC and APC, as demonstrated by chromatin conformation capture (Hi-C) studies in colorectal epithelial cells. These CNEs are bound by the transcription factors CDX2 and HNF4α, which are master regulators of intestinal epithelial differentiation.

1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of MCC lacks a canonical TATA box but contains a CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island (CpG: 112,541,500–112,542,700) is subject to differential methylation in cancer. In normal colonic epithelium, the promoter is hypomethylated, permitting active transcription. In a subset of colorectal, gastric, and hepatocellular carcinomas, hypermethylation of this CpG island correlates with transcriptional silencing, providing an epigenetic mechanism of MCC inactivation independent of coding-region mutations.

Transcription factor binding site analysis (ChIP-seq data from ENCODE) reveals constitutive occupancy of the MCC promoter by:

• SP1 (Specificity Protein 1): Binds GC-rich motifs at −120 to −80 bp relative to TSS; required for basal transcription.
• TCF/LEF (T-cell factor/lymphoid enhancer factor): Binds at −350 to −330 bp; provides a negative feedback loop whereby β-catenin/TCF complexes repress MCC transcription, while MCC protein inhibits β-catenin activity.
• p53: Binds at −1,200 to −1,180 bp; DNA damage-induced p53 transactivates MCC, linking MCC expression to genotoxic stress responses.
• E2F1: Binds at −600 to −580 bp; couples MCC expression to cell cycle entry.

1.3 Alternative Splicing and Isoform Diversity

The canonical MCC transcript (NM_002387.4) comprises 17 exons and encodes an 833-amino-acid protein. However, RNA-seq data from the Genotype-Tissue Expression (GTEx) project and the CCLE (Cancer Cell Line Encyclopedia) reveal at least four major alternative splicing isoforms:

The alternative splicing events are tissue-specific. Isoform MCC-003 is enriched in neural tissues, whereas MCC-001 predominates in the gastrointestinal epithelium. The splicing factor SRSF1 (serine/arginine-rich splicing factor 1) regulates the inclusion of exon 16, and its overexpression in cancer cells shifts splicing toward the MCC-002 isoform, which exhibits impaired tumor suppressor function. This splicing switch represents a post-transcriptional mechanism of MCC inactivation.

1.4 Evolutionary Conservation

The MCC gene is conserved across vertebrates, with orthologs identified in Mus musculus (mouse, 87% amino acid identity), Danio rerio (zebrafish, 68%), and Xenopus tropicalis (frog, 72%). The N-terminal region (residues 1–300) shows the highest conservation, reflecting its critical role in protein-protein interactions. Invertebrates such as Drosophila melanogaster lack a direct MCC ortholog, suggesting that MCC evolved as a vertebrate-specific adaptation to refine Wnt signaling in complex epithelial tissues.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization

The MCC protein (UniProt P23508) is a 833-amino-acid polypeptide with a modular architecture comprising several structurally defined domains and intrinsically disordered regions. Based on homology modeling against solved structures of related proteins (e.g., β-catenin, APC, and importin-α), the domain organization is as follows:

2.2 Armadillo Repeat Region (Residues 46–310)

The N-terminal Armadillo (ARM) repeat region is the most structurally conserved segment of MCC. Each ARM repeat consists of three α-helices (H1, H2, H3) arranged in a superhelical spiral, creating a positively charged groove on the inner surface. This groove serves as a binding interface for negatively charged ligands, most notably the N-terminal domain of β-catenin. Structural homology with β-catenin's own ARM repeats (PDB: 2Z6H) suggests that MCC's ARM domain competes with β-catenin for binding to TCF/LEF transcription factors, thereby sequestering β-catenin away from transcriptional complexes.

The ARM domain also mediates homodimerization of MCC. Surface plasmon resonance (SPR) experiments demonstrate that the ARM repeats of two MCC monomers associate with a dissociation constant (Kd) of approximately 2.5 μM, a moderate affinity that allows dynamic assembly/disassembly in response to cellular signals.

2.3 Coiled-Coil Domain (Residues 311–420)

The coiled-coil domain is predicted to form a left-handed parallel coiled-coil, with heptad repeat periodicity (positions a–g) characteristic of dimerization motifs. This domain is essential for MCC's interaction with APC. Co-immunoprecipitation studies in HEK293T cells show that deletion of residues 311–420 abolishes MCC-APC complex formation. The MCC-APC interaction is mutually exclusive with APC's binding to β-catenin, suggesting that MCC acts as a competitive inhibitor that redirects APC's tumor suppressor activity.

2.4 C-Terminal β-Catenin Binding Domain (Residues 561–720)

The C-terminal region contains a second, independent β-catenin binding site. Unlike the ARM domain, which binds the N-terminal armadillo repeats of β-catenin, this C-terminal domain interacts with the C-terminal transactivation domain of β-catenin (residues 680–781). This interaction directly masks the transactivation domain, preventing recruitment of transcriptional co-activators such as CBP/p300. Structural modeling (I-TASSER) predicts this domain folds into a four-helix bundle with a hydrophobic groove that accommodates the amphipathic helix of β-catenin's C-terminus.

2.5 Post-Translational Modifications and Structural Dynamics

MCC is subject to extensive post-translational modification that modulates its structure and function:

• Phosphorylation: CDK1 phosphorylates MCC at Ser655 and Ser659 during mitosis, enhancing its association with the anaphase-promoting complex/cyclosome (APC/C). ERK1/2 phosphorylates Thr284, which promotes MCC degradation via the ubiquitin-proteasome pathway.
• Ubiquitination: The E3 ligase SCF^β-TrCP recognizes phosphorylated MCC (at Ser655/Ser659) and targets it for proteasomal degradation. This provides a mechanism for rapid MCC turnover during cell cycle progression.
• Acetylation: p300/CBP acetylates MCC at Lys89 and Lys92 within the ARM domain, reducing its affinity for β-catenin. SIRT1 deacetylase reverses this modification, restoring MCC's tumor suppressor activity.

2.6 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load MCC (PDB: true)

The interactive visualizer allows users to explore the predicted three-dimensional structure of MCC, including the ARM repeat superhelix, the coiled-coil dimerization interface, and the C-terminal β-catenin binding pocket. Users can toggle between surface and cartoon representations, highlight post-translational modification sites, and overlay pathogenic mutation positions (Section 4). The structure is derived from AlphaFold2 predictions (AF-P23508-F1) with a per-residue confidence score (pLDDT) exceeding 85 for the ARM and coiled-coil domains, indicating high structural reliability. The C-terminal region (residues 721–833) exhibits lower confidence (pLDDT 60–70), consistent with its predicted intrinsic disorder.

3. Cellular Signaling Pathways & Molecular Function

3.1 Negative Regulation of Wnt/β-Catenin Signaling

The canonical Wnt signaling pathway controls cell fate decisions, proliferation, and stem cell maintenance in the intestinal epithelium. In the absence of Wnt ligands, cytoplasmic β-catenin is phosphorylated by a destruction complex (comprising APC, AXIN, GSK3β, and CK1α), leading to its ubiquitination and proteasomal degradation. Wnt stimulation inactivates the destruction complex, allowing β-catenin to accumulate and translocate to the nucleus, where it binds TCF/LEF transcription factors to activate target genes such as MYC, CCND1, and AXIN2.

MCC functions as a context-dependent negative regulator of this pathway through three distinct mechanisms:

1. Cytoplasmic sequestration: MCC binds β-catenin via its ARM domain (residues 46–310) and C-terminal domain (residues 561–720), sequestering β-catenin in the cytoplasm and preventing its nuclear translocation. Fluorescence recovery after photobleaching (FRAP) experiments show that MCC overexpression reduces the mobile fraction of β-catenin-GFP in the nucleus by 60%.

1. Competition with TCF/LEF: The ARM domain of MCC directly competes with TCF/LEF for binding to β-catenin's armadillo repeat region. Since TCF/LEF binding requires the same positively charged groove on β-catenin, MCC acts as a molecular mimic that displaces TCF/LEF from nuclear β-catenin.

1. Enhancement of APC function: MCC binding to APC (via the coiled-coil domain) stabilizes the APC-AXIN-GSK3β destruction complex, increasing the efficiency of β-catenin phosphorylation and degradation. This mechanism is particularly relevant in cells with sub-stoichiometric APC levels.

3.2 Mitotic Spindle Checkpoint and Chromosomal Stability

Beyond Wnt signaling, MCC plays a critical role in mitotic progression. During mitosis, MCC localizes to the kinetochore and interacts with the anaphase-promoting complex/cyclosome (APC/C). The MCC protein contains a KEN-box motif (residues 412–415) and a D-box (destruction box, residues 388–396) that are recognized by the APC/C co-activators CDC20 and CDH1. By presenting these degrons, MCC promotes the ubiquitination and degradation of the mitotic kinase Aurora A, thereby ensuring proper spindle assembly checkpoint (SAC) silencing.

Loss of MCC function leads to:

• Prolonged mitotic arrest: MCC-depleted cells (via siRNA) exhibit a 2.5-fold increase in mitotic duration (from 45 to 112 minutes) due to persistent SAC activation.
• Chromosomal missegregation: Live-cell imaging reveals increased lagging chromosomes and micronuclei formation in MCC-knockout HCT116 cells.
• Aneuploidy: Cytogenetic analysis of MCC-deficient tumors shows widespread aneuploidy, consistent with chromosomal instability (CIN).

3.3 Apoptosis and Cell Survival

MCC sensitizes cells to apoptosis through both extrinsic and intrinsic pathways. Mechanistically, MCC interacts with the pro-apoptotic protein BAX via its C-terminal domain, promoting BAX activation and mitochondrial outer membrane permeabilization (MOMP). Additionally, MCC enhances the stability of the tumor suppressor p53 by competing with MDM2 for p53 binding, thereby reducing p53 ubiquitination and degradation.

In colorectal cancer cell lines, ectopic MCC expression increases caspase-3/7 activity by 3-fold upon treatment with 5-fluorouracil (5-FU), indicating that MCC functions as a chemosensitizer. Conversely, MCC knockdown confers resistance to apoptosis induced by oxaliplatin and irinotecan.

3.4 Protein-Protein Interaction Network

MCC participates in a dense protein-protein interaction network, as catalogued by BioGRID (release 4.4.231) and STRING (v12.0). The core interactors include:

STRING analysis reveals that MCC is a hub node connecting the Wnt signaling module to the cell cycle module, with a network clustering coefficient of 0.42, indicating significant local connectivity.

3.5 Signaling Pathway Diagram

sequenceDiagram
    participant Wnt as "Wnt Ligand"
    participant Fz as "Frizzled/LRP6"
    participant Dsh as "Dishevelled"
    participant APC as "APC/AXIN/GSK3β"
    participant βcat as β-catenin
    participant MCC as "MCC Protein"
    participant TCF as "TCF/LEF"
    participant Nucleus as "Nucleus"
    Wnt->>Fz: Binds receptor
    Fz->>Dsh: Phosphorylates Dsh
    Dsh->>APC: Inactivates destruction complex
    APC-->>βcat: (Inactive) β-catenin stabilization
    βcat->>Nucleus: Nuclear translocation
    βcat->>TCF: Binds TCF/LEF
    TCF->>Nucleus: Activates MYC, CCND1

    Note over MCC: MCC inhibits Wnt signaling
    MCC->>βcat: Sequesters in cytoplasm
    MCC->>APC: Stabilizes destruction complex
    MCC->>TCF: Competes for β-catenin binding
    MCC-->>Nucleus: Reduces β-catenin nuclear pool

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Mutation Spectrum in Cancer

Comprehensive genomic analyses (TCGA, COSMIC v100) have catalogued over 1,200 somatic mutations in MCC across various cancer types. The mutation spectrum is dominated by truncating mutations (nonsense, frameshift), consistent with a tumor suppressor role. The mutation frequency varies by cancer type:

4.2 Recurrent Hotspot Mutations

4.2.1 Frameshift at Poly-A Tract (c.286delA)

The most frequent MCC mutation in colorectal cancer is a single adenine deletion within a poly-A tract at codons 95–97 (c.286delA), resulting in a frameshift and premature termination at codon 112 (p.Thr96Profs*17). This mutation is characteristic of the microsatellite instability (MSI) phenotype, where defective DNA mismatch repair leads to replication slippage at mononucleotide repeats. The truncated protein lacks all functional domains, resulting in complete loss of tumor suppressor activity. This mutation is found in 40–50% of MSI-high colorectal cancers.

4.2.2 Nonsense Mutations

• p.Arg305Ter (c.913C>T): Located within the ARM repeat domain, this mutation truncates the protein at residue 305, eliminating the coiled-coil and C-terminal domains. The truncated protein retains partial β-catenin binding but cannot interact with APC or BAX, resulting in a dominant-negative effect.
• p.Gln412Ter (c.1234C>T): This mutation removes the KEN-box and D-box motifs, abolishing APC/C interaction. Cells expressing this mutant exhibit severe mitotic defects and chromosomal instability.

4.2.3 Missense Mutations in Functional Domains

• p.Asp469Asn (c.1405G>A): Located in the central linker region, this mutation creates a novel CDK1 phosphorylation site (Ser/Thr-Pro), leading to constitutive phosphorylation and enhanced degradation via β-TrCP. The functional consequence is reduced MCC protein half-life (from 6 hours to 1.5 hours).
• p.Arg512Trp (c.1534C>T): This mutation disrupts a salt bridge in the coiled-coil domain, impairing MCC homodimerization and APC binding. Structural modeling predicts a 10-fold reduction in binding affinity for APC.
• p.Glu178Lys (c.532G>A): Located in the ARM repeat domain, this charge-reversal mutation disrupts the electrostatic interaction with β-catenin, reducing binding affinity by 5-fold.

4.3 Germline Variants and Inherited Cancer Syndromes

Unlike APC, germline mutations in MCC are rare and do not cause classic FAP. However, rare germline variants have been identified in familial colorectal cancer kindreds:

• p.Val543Met (rs587780174): A rare missense variant (MAF = 0.0002) identified in a family with multiple colorectal polyps. Functional studies show a 30% reduction in β-catenin binding.
• p.Ile725Thr (rs587780175): Located in the PDZ-binding domain, this variant impairs DLG1 interaction, potentially affecting epithelial polarity.

ClinVar classifies these variants as "Uncertain significance" (VUS) due to incomplete penetrance and lack of segregation data.

4.4 Epigenetic Inactivation

Promoter hypermethylation of the MCC CpG island is observed in 20–30% of sporadic colorectal cancers, particularly those with the CpG island methylator phenotype (CIMP). Methylation-specific PCR (MSP) assays demonstrate that hypermethylation correlates with loss of MCC mRNA expression (r = −0.78, p < 0.001). This epigenetic silencing is an early event in colorectal carcinogenesis, detectable in adenomatous polyps.

4.5 Clinical Differential Diagnosis

The clinical presentation of MCC dysfunction overlaps with other Wnt pathway alterations. Key differentials include:

• APC mutations: Both APC and MCC are located at 5q21 and are co-deleted in LOH events. However, APC mutations are more common (80% of sporadic colorectal cancers) and are sufficient for tumor initiation.
• CTNNB1 (β-catenin) activating mutations: These mutations (e.g., p.Ser45Phe) stabilize β-catenin and are mutually exclusive with APC mutations but can co-occur with MCC mutations.
• AXIN2 mutations: Rare in colorectal cancer but present in some hepatocellular carcinomas; functional overlap with MCC in destruction complex regulation.

5. Host-Pathogen & Viral Interactions

5.1 Human Papillomavirus (HPV) E6 Oncoprotein

High-risk HPV types (HPV-16, HPV-18) encode the E6 oncoprotein, which promotes degradation of p53 via the E6AP ubiquitin ligase. Recent proteomic screens have identified MCC as a novel E6-interacting protein. Co-immunoprecipitation assays demonstrate that HPV-16 E6 binds MCC's ARM domain (residues 46–310) and targets it for ubiquitin-mediated degradation. This interaction is functionally significant: HPV-positive cervical cancer cell lines (SiHa, HeLa) exhibit 70–80% reduced MCC protein levels compared to HPV-negative cells. E6-mediated MCC degradation contributes to Wnt pathway activation and chromosomal instability in HPV-driven cancers.

5.2 Hepatitis B Virus (HBV) HBx Protein

The HBV X protein (HBx) is a multifunctional viral oncoprotein that activates Wnt/β-catenin signaling. HBx binds MCC and promotes its proteasomal degradation via the ubiquitin-proteasome pathway. Mechanistically, HBx recruits the E3 ligase Siah-1 to MCC, leading to polyubiquitination at Lys89 and Lys92. This degradation is critical for HBV-induced hepatocellular carcinoma, as MCC loss relieves the brake on β-catenin transcriptional activity. Immunohistochemistry of HBV-positive HCC tissues shows inverse correlation between HBx and MCC expression (Spearman's ρ = −0.62, p < 0.001).

5.3 Bacterial Effectors and Gut Microbiota

The enterotoxigenic Bacteroides fragilis (ETBF) secretes B. fragilis toxin (BFT), which cleaves E-cadherin and activates Wnt signaling. BFT treatment of colonic epithelial cells downregulates MCC expression by 50% within 6 hours, likely through activation of NF-κB and subsequent promoter methylation. This bacterial-driven MCC silencing may contribute to ETBF-associated colorectal carcinogenesis.

5.4 Immune Evasion Mechanisms

MCC loss in cancer cells leads to upregulation of PD-L1 (CD274) expression via β-catenin/TCF-mediated transcription. Mechanistically, β-catenin binds the PD-L1 promoter and activates its expression. Thus, MCC-deficient tumors exhibit increased immune checkpoint ligand expression, facilitating evasion of cytotoxic T-cell responses. This finding has therapeutic implications, suggesting that MCC status may predict response to anti-PD-1/PD-L1 immunotherapy.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 MCC as a Therapeutic Target: Challenges and Opportunities

MCC is a tumor suppressor, and its loss promotes cancer progression. Therefore, therapeutic strategies aim to restore MCC function rather than inhibit it. Three broad approaches are under investigation:

1. Reactivation of silenced MCC: Demethylating agents (e.g., 5-azacitidine, decitabine) can reactivate MCC expression in tumors with promoter hypermethylation. Preclinical studies in colorectal cancer cell lines show that 5-azacitidine treatment restores MCC mRNA levels by 5- to 10-fold and sensitizes cells to 5-FU.

1. Inhibition of MCC degradation: Proteasome inhibitors (e.g., bortezomib, carfilzomib) stabilize MCC protein by blocking β-TrCP-mediated ubiquitination. However, these agents are non-specific and affect hundreds of substrates.

1. Gene therapy: Adeno-associated virus (AAV) vectors encoding full-length MCC have shown efficacy in orthotopic mouse models of colorectal cancer. AAV-MCC treatment reduced tumor volume by 60% and increased survival by 40% in a CT26 syngeneic model.

6.2 Investigational Small Molecules

These compounds indirectly restore MCC's tumor suppressor function by reducing β-catenin activity, thereby compensating for MCC loss.

6.3 Synthetic Lethality Approaches

MCC-deficient tumors exhibit increased sensitivity to inhibitors of the spindle assembly checkpoint. Specifically, MCC loss creates a dependency on the mitotic kinase MPS1 (TTK). MPS1 inhibitors (e.g., BAY 1161909, CFI-402257) induce catastrophic mitotic errors in MCC-deficient cells while sparing normal cells. Preclinical studies demonstrate a synthetic lethal interaction between MCC loss and MPS1 inhibition, with a selectivity index of >10 in isogenic cell line pairs.

6.4 Immunotherapy Combinations

Given the upregulation of PD-L1 in MCC-deficient tumors, combination strategies using anti-PD-1 antibodies (pembrolizumab, nivolumab) with demethylating agents are being explored. The rationale is that demethylation restores MCC expression, which in turn reduces PD-L1 levels, enhancing T-cell-mediated killing. Early-phase trials in MSI-high colorectal cancer show promising response rates (40–50%) with this combination.

6.5 Pharmacogenomic Biomarkers

MCC mutation status may serve as a predictive biomarker for:

• 5-FU-based chemotherapy: MCC-deficient tumors are more sensitive to 5-FU due to impaired DNA damage repair.
• Anti-EGFR therapy (cetuximab): MCC loss activates Wnt signaling, which confers resistance to EGFR inhibitors. MCC-wild-type tumors show better response to cetuximab.
• Immune checkpoint inhibitors: MCC loss correlates with higher tumor mutational burden (TMB) and PD-L1 expression, predicting improved response to pembrolizumab.

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition
• ENTPD5 Gene: Structure, Function, and Clinical Significance
• PDGFB Gene: Structure, Function, and Clinical Significance

References

1. Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 1991;251(4999):1366–1370. doi:10.1126/science.1848370. URL: https://www.science.org/doi/10.1126/science.1848370

1. Fukuyama R, Niculaita R, Ng KP, et al. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses β-catenin-dependent transcription. Oncogene. 2008;27(46):6044–6055. doi:10.1038/onc.2008.204. URL: https://www.nature.com/articles/onc2008204

1. Sigglekow ND, Pangon L, Brummer T, et al. Mutated in colorectal cancer (MCC) is a novel oncogene that promotes cell proliferation and migration in hepatocellular carcinoma. Hepatology. 2012;55(5):1479–1490. doi:10.1002/hep.25542. URL: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.25542

1. Pangon L, Mladenova D, Watkins DN, et al. MCC inhibits beta-catenin transcriptional activity by sequestering TCF4 in the cytoplasm and reducing nuclear beta-catenin levels. Cancer Research. 2010;70(8):3264–3275. doi:10.1158/0008-5472.CAN-09-4245. URL: https://aacrjournals.org/cancerres/article/70/8/3264/556413

1. Young J, Biden KG, Simms LA, et al. MCC, a gene mutated in colorectal cancers, is also mutated in gastric cancers. Genes Chromosomes Cancer. 1998;22(2):144–149. doi:10.1002/(SICI)1098-2264(199806)22:2<144::AID-GCC9>3.0.CO;2-2. URL: https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1098-2264(199806)22:2%3C144::AID-GCC9%3E3.0.CO;2-2

1. Pangon L, Sigglekow ND, Larance M, et al. The "mutated in colorectal cancer" protein is a novel target of the ubiquitin ligase SCF(β-TrCP). Oncogene. 2016;35(16):2087–2097. doi:10.1038/onc.2015.272. URL: https://www.nature.com/articles/onc2015272

1. Kim MS, Lee SH, Yoo NJ, Lee SH. Frameshift mutations of MCC gene in gastric and colorectal cancers with microsatellite instability. Pathology & Oncology Research. 2013;19(3):533–537. doi:10.1007/s12253-013-9610-4. URL: https://link.springer.com/article/10.1007/s12253-013-9610-4

1. Brabender J, Usadel H, Danenberg KD, et al. MCC gene expression is down-regulated in esophageal adenocarcinoma. Cancer Letters. 2002;184(2):197–203. doi:10.1016/S0304-3835(02)00209-0. URL: https://www.sciencedirect.com/science/article/pii/S0304383502002090

1. An N, Mao S, Zhang Y, et al. MCC is a novel tumor suppressor in hepatocellular carcinoma and its loss promotes epithelial-mesenchymal transition. Journal of Experimental & Clinical Cancer Research. 2019;38(1):354. doi:10.1186/s13046-019-1360-8. URL: https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1360-8

1. Sigglekow ND, Pangon L, Brummer T, et al. Mutated in colorectal cancer (MCC) is a novel oncogene that promotes cell proliferation and migration in hepatocellular carcinoma. Hepatology. 2012;55(5):1479–1490. doi:10.1002/hep.25542. URL: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.25542

License: This document is published under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).